Form 4: United Therapeutics CEO Executes Planned Stock Sale

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• The acquired shares were subsequently sold in multiple transactions on June 8, 2026.
• The sales were executed at weighted average prices ranging from $544.89 to $551.37 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine, pre-planned divestment by an executive rather than a discretionary sale based on current market sentiment.

Positives

• The transactions were part of a pre-planned 10b5-1 program, indicating the sales were not based on non-public information.
• The CEO maintains a significant remaining equity stake in the company, including 40,513 shares held directly and substantial holdings in various family trusts.

Negatives

• The transaction represents a reduction in the CEO's direct beneficial ownership of common stock.

Risks

• The 10b5-1 plan is scheduled to continue until December 31, 2026, or until 1,734,410 options are exercised, which may lead to further periodic selling pressure.

Future Outlook

The reporting person's 10b5-1 plan remains active and is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 total options.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for executives in the biotechnology sector to manage personal liquidity and diversify holdings, and generally does not signal a lack of confidence in company performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is a best-practice standard for corporate executives to avoid potential conflicts of interest regarding insider trading regulations.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive compensation and liquidity management strategies observed in large-cap biotech firms.

Related Party Transactions

• The filing discloses shares held by the reporting person's spouse and various family trusts where the reporting person or family members are beneficiaries.

Stakeholder Impact

• Minimal impact on shareholders as the sales are pre-planned and systematic.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, 10b5-1, Biotech, Stock Options